Healthcare / Drug Manufacturers: General
Amgen Inc.AMGN
Amgen discovers, makes and sells medicines, mostly biologics, reported as one business: for heart disease (Repatha), bone loss (Prolia, EVENITY), inflammation (ENBREL, TEZSPIRE, Otezla), cancer (BLINCYTO, IMDELLTRA) and rare diseases (TEPEZZA, KRYSTEXXA, UPLIZNA).
- Edition
- Nov 6, 2026
- Covers
- Q3 2026
- Length
- 8 pages
In This Report
- 1SummaryThe takeaway, the case for and what could go wrong
- 2Financial HealthSales, margins, cash flow and debt over the years
- 3Business TrendsThe segments and the operating numbers the company reports
- 4Dividend ProfileThe dividend's record, its growth, and how well cash and earnings cover it
- 5Yield HistoryToday's yield against its own five and ten-year range
- 6ValuationThe price against the stock's own history and the intrinsic value models
- 7Outlook and RisksAnalyst estimates, guidance and the risks to watch
- 8MethodologyGlossary, sources and disclosures